Trial Profile
Effect of 90-yttrium-Ibritumomab Tiuxetan in patients with Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2015
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 13 May 2015 New trial record